155 related articles for article (PubMed ID: 22301192)
1. Novel agents for the treatment of HIV-2 infection.
Peterson K; Rowland-Jones S
Antivir Ther; 2012; 17(3):435-8. PubMed ID: 22301192
[TBL] [Abstract][Full Text] [Related]
2. Baseline susceptibility of primary HIV-2 to entry inhibitors.
Borrego P; Calado R; Marcelino JM; Bártolo I; Rocha C; Cavaco-Silva P; Doroana M; Antunes F; Maltez F; Caixas U; Barroso H; Taveira N
Antivir Ther; 2012; 17(3):565-70. PubMed ID: 22293827
[TBL] [Abstract][Full Text] [Related]
3. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
Kramer VG; Schader SM; Oliveira M; Colby-Germinario SP; Donahue DA; Singhroy DN; Tressler R; Sloan RD; Wainberg MA
Antimicrob Agents Chemother; 2012 Aug; 56(8):4154-60. PubMed ID: 22615275
[TBL] [Abstract][Full Text] [Related]
4. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
[TBL] [Abstract][Full Text] [Related]
5. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
Arribas JR
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
[TBL] [Abstract][Full Text] [Related]
6. HIV entry inhibitors: progress in development and application.
Lai WH; Huang L; Chen CH
Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations.
Alencar CS; Nishiya AS; Ferreira S; Giret MT; Diaz RS; Sabino EC
AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1267-71. PubMed ID: 20977300
[TBL] [Abstract][Full Text] [Related]
8. Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists].
McKinnell JA; Saag MS
Curr Opin HIV AIDS; 2009 Nov; 4(6):513-7. PubMed ID: 20048719
[TBL] [Abstract][Full Text] [Related]
9. Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.
Férir G; Palmer KE; Schols D
Virology; 2011 Sep; 417(2):253-8. PubMed ID: 21802104
[TBL] [Abstract][Full Text] [Related]
10. Entry inhibitors in the treatment of HIV-1 infection.
Tilton JC; Doms RW
Antiviral Res; 2010 Jan; 85(1):91-100. PubMed ID: 19683546
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.
Espirito-Santo M; Santos-Costa Q; Calado M; Dorr P; Azevedo-Pereira JM
AIDS Res Hum Retroviruses; 2012 May; 28(5):478-85. PubMed ID: 21902586
[TBL] [Abstract][Full Text] [Related]
12. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
Tilton JC; Wilen CB; Didigu CA; Sinha R; Harrison JE; Agrawal-Gamse C; Henning EA; Bushman FD; Martin JN; Deeks SG; Doms RW
J Virol; 2010 Oct; 84(20):10863-76. PubMed ID: 20702642
[TBL] [Abstract][Full Text] [Related]
13. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
[TBL] [Abstract][Full Text] [Related]
14. HIV-2 susceptibility to entry inhibitors.
Borrego P; Taveira N
AIDS Rev; 2013; 15(1):49-61. PubMed ID: 23449229
[TBL] [Abstract][Full Text] [Related]
15. Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.
Rossetti B; Bianco C; Bellazzi LI; Bruzzone B; Colao G; Corsi P; Monno L; Pagano G; Paolucci S; Punzi G; Setti M; Zazzi M; De Luca A
AIDS Res Hum Retroviruses; 2014 Jan; 30(1):17-24. PubMed ID: 23971941
[TBL] [Abstract][Full Text] [Related]
16. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of viral entry.
Melby T; Westby M
Handb Exp Pharmacol; 2009; (189):177-202. PubMed ID: 19048201
[TBL] [Abstract][Full Text] [Related]
18. In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.
Visseaux B; Charpentier C; Hurtado-Nedelec M; Storto A; Antoine R; Peytavin G; Damond F; Matheron S; Brun-Vézinet F; Descamps D;
Antimicrob Agents Chemother; 2012 Jan; 56(1):137-9. PubMed ID: 22064539
[TBL] [Abstract][Full Text] [Related]
19. [Conclusions and perspectives. Maraviroc].
Alcamí J
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():49-54. PubMed ID: 19133222
[TBL] [Abstract][Full Text] [Related]
20. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.
Yost R; Pasquale TR; Sahloff EG
Am J Health Syst Pharm; 2009 Apr; 66(8):715-26. PubMed ID: 19336831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
